17,261 trials
Adenocarcinoma of the Prostate · Stage II Prostate Cancer · Stage III Prostate Cancer
Primary: Incidence of Acute and Chronic Grade 3 or Greater Toxicity as Evaluated Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)…
Asthma
Primary: Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period — -0.002; -0.001; -0.034; -0.031 Liters
Breast Cancer
Primary: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) — 3; 9; 2; 1 participants
Dengue Fever · Dengue Hemorrhagic Fever · Dengue Shock Syndrome
Primary: Safety: Incidence of All and Grade 3 Solicited Local Symptoms — 114; 98; 84; 55 number of occurances
Chronic Lymphocytic Leukemia
Primary: Percent of Patients Who Complete an Accelerated Infusion Regimen Within 15 Minutes of the Planned 2-hour Treatment. — 84 percentage of participants
Prostate Cancer
Primary: Number of Participants Free From Progression at 3 Years — 54 participants
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Amyloidosis
Primary: Amyloid Cardiomyopathy: BNP — 883 pg/mL — p=0.035
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Cannabis Dependence · Cannabis Withdrawal · Cognitive Deficits
Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…
Nicotine Dependence
Primary: Percent Participants Abstinent From Smoking During Study Weeks 7-10 — 5; 6 Participants
Opioid Dependence
Primary: Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6) — -1.25; -0.36 opioid-positive urine — p=.42
Hepatoblastoma · Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Number of Participants With Overall Response — 0; 1; 0; 0 Patients
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Effectiveness Endpoint for the Pulsar Stent: Primary Patency — 66.8 Percentage of participants